Evidence

BROWSE BY STUDY TYPE OR CONFERENCE
All
  • All
  • MODEL VALIDATION
  • CLINICAL VALIDATION
  • AACR
  • ASCO
  • ASH
BROWSE BY YEAR
All
  • All
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • Archive
Personalized Therapy Design for Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Using Computational Biology Modeling with in Vitro Validation

Blood Journal,

The Oral Proteasome Inhibitor Ixazomib, Alone and in Combination with Ibrutinib, Induces Lethality in Waldenstrom Macroglobulinemia Cells That Are Resistant to Ibrutinib

Blood Journal,

Predicting Response to CDK4/6 Inhibitors and Combinations Using a Computational Biology Model and it's Validation: A Beat AML Project Study

Blood Journal,

Predicting Response to BET Inhibitors Using a Computational Model and it's Validation: A Beat AML Project Study

Blood Journal,

Predicting Response to IDH1/IDH2 Inhibitors Beyond IDH Mutations Using a Computational Model and it's Validation: A Beat AML Project Study

Blood Journal,

Digital Drug Screening and Computational Modeling Identifies Treatment Opportunities Despite Lack of Directly Actionable Mutations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Blood Journal,

A Genomic Signature Predicting Venetoclax Treatment Response in Acute Myeloid Leukemia (AML) Identified By Protein Network Mapping and Validated By Ex Vivo Drug Sensitivity Testing

Blood Journal,

Icare 1: A Prospective Clinical Trial to Predict Treatment Response Based on Mutanome-Informed Computational Biology in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Blood Journal,

STAY INFORMED

Top